.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,414,008

« Back to Dashboard

Details for Patent: 6,414,008

Title: Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
Abstract:New disubstituted bicyclic heterocycles of general formula Compounds of general formula I, wherein E is an R.sub.b NH--C(.dbd.NH)-- group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E is a cyano group, are valuable intermediates for preparing the other compounds of general formula I.
Inventor(s): Hauel; Norbert (Schemmerhofen, DE), Priepke; Henning (Warthausen, DE), Ries; Uwe (Biberach, DE), Stassen; Jean Marie (Warthausen, DE), Wienen; Wolfgang (Biberach, DE)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Filing Date:Oct 13, 2000
Application Number:09/688,260
Claims:1. A compound of the formula I

wherein:

A is a carbonyl or sulfonyl group linked to the benzo moiety of the group Het, wherein the benzo moiety may not contain an R.sub.1 group;

B is an ethylene group, wherein a methylene group, linked either to the group Het or Ar, is optionally replaced by an oxygen or sulfur atom or by a sulfinyl, sulfonyl, carbonyl, or --NR.sub.1 -- group, wherein

R.sub.1 is a hydrogen atom or a C.sub.1-6 -alkyl group;

E is a cyano or R.sub.b NH--C(.dbd.NH)-- group, wherein

R.sub.b is a hydrogen atom or a hydroxy, C.sub.1-9 -alkoxycarbonyl, cyclohexyloxycarbonyl, phenyl-C.sub.1-3 -alkoxycarbonyl, benzoyl, p-C.sub.1-3 -alkyl-benzoyl, or pyridinoyl group, wherein the ethoxy moiety in the 2-position of the abovementioned C.sub.1-9 -alkoxycarbonyl group is unsubstituted or additionally substituted by a C.sub.1-3 -alkylsulfonyl or 2-(C.sub.1-3 -alkoxy)-ethyl group;

Ar is a phenylene or naphthylene group optionally substituted by a fluorine, chlorine, or bromine atom or by a trifluoromethyl, C.sub.1-3 -alkyl, or C.sub.1-3 -alkoxy group, or a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene, or pyridazinylene group optionally substituted in the carbon skeleton by a C.sub.1-3 -alkyl group;

Het is a bicyclic heterocycle of formula ##STR9##

wherein

X is a nitrogen atom, and

Y is an oxygen or sulfur atom or an imino group optionally substituted by a C.sub.1-6 -alkyl or C.sub.3-7 -cycloalkyl group whilst additionally one or two non-angular methyne groups in the phenyl moiety of the above-mentioned bicyclic heterocycle may each be replaced by a nitrogen atom; or

X is a methyne group optionally substituted by the group R.sub.1, wherein R.sub.1 is as hereinbefore defined, and

Y is a nitrogen atom optionally substituted by a C.sub.1-6 -alkyl or C.sub.3-7 -cycloalkyl group;

R.sub.a is a C.sub.1-6 -alkyl group, a C.sub.3-7 -cycloalkyl group optionally substituted by a C.sub.1-3 -alkyl group, wherein the C.sub.1-3 -alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted in vivo into a carboxy group, or

R.sub.a is a R.sub.2 NR.sub.3 -- group, wherein

R.sub.2 is a C.sub.1-4 -alkyl group optionally substituted by a carboxy, C.sub.1-6 -alkyloxycarbonyl, benzyloxycarbonyl, C.sub.1-3 -alkylsulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, trifluorosulfonylamino, trifluorosulfonylaminocarbonyl, or 1H-tetrazolyl group, or

a C.sub.2-4 -alkyl group substituted at a carbon which is other than the one in the .alpha.-position relative to the adjacent nitrogen atom, by a hydroxy, phenyl-C.sub.1-3 -alkoxy, carboxy-C.sub.1-3 -alkylamino, C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino, N--(C.sub.1-3 -alkyl)-carboxy-C.sub.1-3 -alkylamino or N--(C.sub.1-3 -alkyl)-C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino group, or

a piperidinyl group optionally substituted by a C.sub.1-3 -alkyl group; and

R.sub.3 is a hydrogen atom, a C.sub.1-6 -alkyl group, a C.sub.3-7 -cycloalkyl group optionally substituted by a C.sub.1-3 -alkyl group or a C.sub.3-6 -alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R.sub.2 NR.sub.3 -- group, or a oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, or imidazolyl group, or

R.sub.2 and R.sub.3 together with the nitrogen atom between them are a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxymethyl or C.sub.1-4 -alkoxycarbonyl group, onto which a phenyl ring may additionally be fused,

or, if E is a group of the formula R.sub.b NH--C(.dbd.NH)--, a physiologically acceptable salt thereof or, if E is a cyano group, a salt thereof.

2. The compound of the formula I according to claim 1, wherein E is an R.sub.b NH--C(.dbd.NH)-- group, wherein:

R.sub.b is a hydrogen atom or a hydroxy, C.sub.1-9 -alkoxycarbonyl, cyclohexyloxycarbonyl, phenyl-C.sub.1-3 -alkoxycarbonyl, benzoyl, p-C.sub.1-3 -alkyl-benzoyl, or pyridinoyl group, wherein the ethoxy moiety in the 2-position of the abovementioned C.sub.1-9 -alkoxycarbonyl group is unsubstituted or additionally substituted by a C.sub.1-3 -alkylsulfonyl or 2-(C.sub.1-3 -alkoxy)-ethyl group.

3. The compound of the formula I according to claim 1, wherein:

X is a nitrogen atom, and

Y is an oxygen or sulfur atom or an imino group optionally substituted by a C.sub.1-6 -alkyl or C.sub.3-7 -cycloalkyl group whilst additionally one or two non-angular methyne groups in the phenyl moiety of the above-mentioned bicyclic heterocycle may each be replaced by a nitrogen atom.

4. The compound of the formula I according to claim 1, wherein:

X is a methyne group optionally substituted by the group R.sub.1, wherein R.sub.1 is hydrogen atom or a C.sub.1-6 -alkyl group, and

Y is a nitrogen atom optionally substituted by a C.sub.1-6 -alkyl or C.sub.3-7 -cycloalkyl group.

5. The compound of the formula I according to claim 1, wherein R.sub.a is a R.sub.2 NR.sub.3 -- group and wherein:

R.sub.2 is a C.sub.1-4 -alkyl group optionally substituted by a carboxy, C.sub.1-6 -alkyloxycarbonyl, benzyloxycarbonyl, C.sub.1-3 -alkylsulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, trifluorosulfonylamino, trifluorosulfonylaminocarbonyl, or 1H-tetrazolyl group, or

a C.sub.2-4 -alkyl group substituted at a carbon which is other than the one in the .alpha.-position relative to the adjacent nitrogen atom, by a hydroxy, phenyl-C.sub.1-3 -alkoxy, carboxy-C.sub.1-3 -alkylamino, C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino, N--(C.sub.1-3 -alkyl)-carboxy-C.sub.1-3 -alkylamino or N--(C.sub.1-3 -alkyl)-C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino group, or

a piperidinyl group optionally substituted by a C.sub.1-3 -alkyl group; and

R.sub.3 is a hydrogen atom, a C.sub.1-6 -alkyl group, a C.sub.3-7 -cycloalkyl group optionally substituted by a C.sub.1-3 -alkyl group or a C.sub.3-6 -alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R.sub.2 NR.sub.3 -- group, or a oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, or imidazolyl group, or

R.sub.2 and R.sub.3 together with the nitrogen atom between them are a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxymethyl or C.sub.1-4 -alkoxycarbonyl group, onto which a phenyl ring may additionally be fused,

or, if E is a group of the formula R.sub.b NH--C--(.dbd.NH)--, a physiologically acceptable salt thereof or, if E is a cyano group, a salt thereof.

6. The compound of the formula I according to claim 1, wherein R.sub.a is a R.sub.2 NR.sub.3 -- group and wherein:

R.sub.2 is a C.sub.1-4 -alkyl group substituted by a carboxy, C.sub.1-6 -alkyloxycarbonyl, benzyloxycarbonyl, C.sub.1-3 -alkylsulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, trifluorosulfonylamino, trifluorosulfonylaminocarbonyl, or 1H-tetrazolyl group, or

a C.sub.2-4 -alkyl group substituted at a carbon which is other than the one in the .alpha.-position relative to the adjacent nitrogen atom, by a hydroxy, phenyl-C.sub.1-3 -alkoxy, carboxy-C.sub.1-3 -alkylamino, C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino, N--(C.sub.1-3 -alkyl)-carboxy-C.sub.1-3 -alkylamino or N--(C.sub.1-3 -alkyl)-C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino group; and

R.sub.3 is a hydrogen atom, a C.sub.1-6 -alkyl group, a C.sub.3-7 -cycloalkyl group substituted by a C.sub.1-3 -alkyl group or a C.sub.3-6 -alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R.sub.2 NR.sub.3 -- group, or an oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, or imidazolyl group, or

R.sub.2 and R.sub.3 together with the nitrogen atom between them are a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxymethyl or C.sub.1-4 -alkoxycarbonyl group, onto which a phenyl ring may additionally be fused,

or, if E is a group of the formula R.sub.b NH--C--(.dbd.NH)--, a physiologically acceptable salt thereof or, if E is a cyano group, a salt thereof.

7. The compound of the formula I according to claim 1, wherein Het is a 1-(C.sub.1-3 -alkyl)-2,5-benzimidazolylene, 1-cyclopropyl-2,5-benzimidazolylene, 2,5-benzothiazolylene, 1-(C.sub.1-3 -alkyl)-2,5-indolylene, 1-(C.sub.1-3 -alkyl)-2,5-imidazo[4,5-b]pyridinylene, 3-(C.sub.1-3 -alkyl)-2,7-imidazo[1,2-a]pyridinylene, or 1-(C.sub.1-3 -alkyl)-2,5-thieno[2,3-d]imidazolylene group.

8. A compound selected from the group consisting of:

(a) 3-Methyl-2-[2-(4-amidinophenyl)ethyl]imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide;

(b) 3-Methyl-2-[2-(4-amidinophenyl)ethyl]imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)amide;

(c) 3-Methyl-2-[2-(4-amidinophenyl)ethyl]imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)amide hydrochloride;

(d) 3-Methyl-2-[2-(4-amidinophenyl)ethyl]imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-ethoxycarbonylmethylamide hydrochloride;

(e) 3-Methyl-2-[2-(4-amidinophenyl)ethyl]imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-hydroxycarbonylmethylamide hydrochloride;

(f) 2-[2-(4-amidinophenyl)ethyl]-3-methyl-6-(2-methoxycarbonyl-2,3-dihydroindo l-1-yl-carbonyl)imidazo[4,5-b]pyridine hydrochloride;

(g) 2-[2-(4-amidinophenyl)ethyl]-3-methyl-6-(2-carboxy-2,3-dihydroindol-1-yl-c arbonyl)imidazo[4,5-b]pyridine hydrochloride;

(h) 1-Methyl-2-[(4-amidinophenyl)oxymethyl]imidazo[4,5-b]pyridin-5-yl-carboxyl ic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide;

(i) 1,5-Dimethyl-2-[(4-cyanophenyl)oxymethyl]imidazo[4,5-b]pyridine;

(j) 2-[N-(4-amidinophenyl)aminomethyl]benzothiazole-5-carboxylic acid-N-phenyl-N-(2-carboxyethyl)amide;

(k) 2-[N-(4-amidinophenyl)aminomethyl]benzothiazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)amide dihydrochloride;

(l) 2-[2-(4-amidinophenyl)ethyl]benzothiazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)amide dihydrochloride;

(m) 2-[N-(4-amidinophenyl)aminomethyl]benzothiazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)amide dihydrochloride;

(n) 2-[N-(4-amidinophenyl)aminomethyl]benzothiazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)amide dihydrochloride;

(o) 2-[N-(4-amidinophenyl)-N-methylaminomethyl]benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide hydrochloride;

(p) 2-[N-(4-amidinophenyl)-N-methylaminomethyl]benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)amide hydrochloride;

(q) 2-[(4-amidinophenyl)thiomethyl]benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide hydrochloride;

(r) 2-[(4-amidinophenyl)thiomethyl]benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)amide hydrochloride;

(s) 2-[N-(4-amidinophenyl)aminomethyl]benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)amide hydrochloride;

(t) 2-[N-(4-amidinophenyl)aminomethyl]benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(hydroxycarbonylmethyl)amide hydrochloride;

(u) 2-[2-(4-amidinophenyl)ethyl]benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide hydrochloride;

(v) 2-[2-(4-amidinophenyl)ethyl]benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)amide hydrochloride;

(w) 2[N-(4amidinophenyl)aminomethyl]benzothiazol-5-yl-carboxylic acid-N-(n-propyl)-N-2-ethoxycarbonylethyl)amide hydrochloride;

(x) 2-[N-(4-amidinophenyl)aminomethyl]benzothiazol-5-yl-carboxylic acid-N-(n-propyl)-N-(2-hydroxycarbonylethyl)amide hydrochloride,

or a physiologically acceptable salt thereof.

9. 3-Methyl-2-[2-(4-amidinophenyl)ethyl]imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)amide, or a physiologically acceptable salt thereof.

10. 2-[N-(4-amidinophenyl)aminomethyl]benzothiazole-5-carboxylic acid-N-phenyl-N-(2-carboxyethyl)amide, or a physiologically acceptable salt thereof.

11. A compound of the formula I according to claim 1, wherein:

B is an ethylene group, wherein a methylene group linked to the group Ar, is optionally replaced by an oxygen or sulfur atom or by an --NR.sub.1 -- group, wherein

R.sub.1 is a hydrogen atom or a methyl group;

E is an R.sub.b NH--C(.dbd.NH)-- group, wherein

R.sub.b is a hydrogen atom or a hydroxy, C.sub.1-9 -alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p-C.sub.1-3 -alkylbenzoyl or nicotinoyl group, wherein the ethoxy moiety in the 2-position of the abovementioned C.sub.1-9 -alkoxycarbonyl group is unsubstituted or additionally substituted by a C.sub.1-3 -alkylsulfonyl or 2-(C.sub.1-3 -alkoxy)-ethyl group,

Ar is a 1,4-phenylene group optionally substituted by a chlorine atom or by a methyl, ethyl, or methoxy group, or is a 2,5-thienylene group;

Het is a 1-methyl-2,5-benzimidazolylene, 1-cyclopropyl-2,5-benzimidazolylene, 2,5-benzothiazolylene, 1-methyl-2,5-indolylene, 1-methyl-2,5-imidazo[4,5-b]pyridinylene, 3-methyl-2,7-imidazo[1,2-a]pyridinylene or 1-methyl-2,5-thieno[2,3-d]imidazolylene group; and

R.sub.a is a R.sub.2 NR.sub.3 -- group, wherein

R.sub.2 is a C.sub.1-3 -alkyl group optionally substituted by a carboxy, C.sub.1-6 -alkyloxycarbonyl, benzyloxycarbonyl, methylsulfonylaminocarbonyl, or 1H-tetrazol-5-yl group,

a C.sub.2-4 -alkyl group substituted at a carbon which is other than the one at the .alpha.-position relative to the adjacent nitrogen atom, by a hydroxy, benzyloxy, carboxy-C.sub.1-3 -alkylamino, C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino, N--(C.sub.1-3 -alkyl)-carboxy-C.sub.1-3 -alkylamino, or N--(C.sub.1-3 -alkyl)-C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino group, and

R.sub.3 is a propargyl group, wherein the unsaturated moiety is not be linked directly to the nitrogen atom of the R.sub.2 NR.sub.3 -- group, is a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, or is a pyridinyl group,

or a tautomer or salt thereof.

12. A compound of the formula I according to claim 1, wherein:

A is a carbonyl group linked to the benzo moiety of the group Het,

B is an ethylene group, wherein a methylene group attached to the group Ar is optionally replaced by an --NR.sub.1 group, wherein

R.sub.1 is a hydrogen atom or a methyl group;

E is an R.sub.b NH--C(.dbd.NH)-- group, wherein

R.sub.b is a hydrogen atom, a hydroxy, C.sub.1-9 -alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p-C.sub.1-3 -alkyl-benzoyl, or nicotinoyl group, wherein the ethoxy moiety in the 2-position of the abovementioned C.sub.1-9 -alkoxycarbonyl group is unsubstituted or additionally substituted by a methylsulfonyl or 2-ethoxyethyl group;

Ar is a 1,4-phenylene group optionally substituted by a methoxy group or it is a 2,5-thienylene group;

Het is a 1-methyl-2,5-benzimidazolylene, 2,5-benzothiazolylene, 1-methyl-2,5-indolylene, or 1-methyl-2,5-thieno[2,3-d]imidazolylene group; and

R.sub.a is an R.sub.2 NR.sub.3 -- group, wherein

R.sub.2 is a C.sub.1-3 -alkyl group optionally substituted by a carboxy, C.sub.1-6 -alkyloxycarbonyl, benzyloxycarbonyl, methylsulfonylaminocarbonyl, or 1H-tetrazol-5-yl group,

a C.sub.2-3 -alkyl group substituted at a carbon which is other than the one at the .alpha.-position relative to the adjacent nitrogen atom, by a hydroxy, benzyloxy, carboxy-C.sub.1-3 -alkylamino, C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino, N--(C.sub.1-3 -alkyl)-carboxy-C.sub.1-3 -alkylamino, or N--(C.sub.1-3 -alkyl)-C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkylamino group, and

R.sub.3 is a phenyl group optionally substituted by a fluorine atom, or is a 2-pyridinyl group,

or a tautomer or salt thereof.

13. A physiologically acceptable salt of a compound according to claim 1, wherein E is an R.sub.b NH--C(.dbd.NH)-- group.

14. A physiologically acceptable salt of a compound according to claim 2.

15. A physiologically acceptable salt of a compound according to claim 3, wherein E is an R.sub.b NH--C(.dbd.NH)-- group.

16. A physiologically acceptable salt of a compound according to claim 4, wherein E is an R.sub.b NH--C(.dbd.NH)-- group.

17. A physiologically acceptable salt of a compound according to claim 5, wherein E is an R.sub.b NH--C(.dbd.NH)-- group.

18. A physiologically acceptable salt of a compound according to claim 6, wherein E is an R.sub.b NH--C(.dbd.NH)-- group.

19. A physiologically acceptable salt of a compound according to claim 7, wherein E is an R.sub.b NH--C(.dbd.NH)-- group.

20. A physiologically acceptable salt of a compound according to claim 8.

21. A physiologically acceptable salt of a compound according to claim 11.

22. A physiologically acceptable salt of a compound according to claim 12.

23. A pharmaceutical composition comprising a physiologically acceptable compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

24. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier or diluent.

25. A pharmaceutical composition comprising a physiologically acceptable compound according to claim 3 and a pharmaceutically acceptable carrier or diluent.

26. A pharmaceutical composition comprising a physiologically acceptable compound according to claim 4 and a pharmaceutically acceptable carrier or diluent.

27. A pharmaceutical composition comprising a physiologically acceptable compound according to claim 5 and a pharmaceutically acceptable carrier or diluent.

28. A pharmaceutical composition comprising a physiologically acceptable compound according to claim 6 and a pharmaceutically acceptable carrier or diluent.

29. A pharmaceutical composition comprising a physiologically acceptable compound according to claim 7 and a pharmaceutically acceptable carrier or diluent.

30. A pharmaceutical composition comprising a compound according to claim 8 and a pharmaceutically acceptable carrier or diluent.

31. A pharmaceutical composition comprising a compound according to claim 11 and a pharmaceutically acceptable carrier or diluent.

32. A pharmaceutical composition comprising a compound according to claim 12 and a pharmaceutically acceptable carrier or diluent.

33. A method for the prophylaxis or treatment of venous and arterial thrombotic disease in a patient in need thereof, which comprises administering to the patient an antithrombotic amount of a compound according one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, wherein E is an R.sub.b NH--C(.dbd.NH)-- group or a physiologically acceptable salt thereof.

34. The method of claim 33, wherein the thrombotic disease is selected from the group consisting of: deep leg vein thrombosis, reocclusion after a bypass operation or angioplasty (PT(C)A), occlusion in peripheral arterial disease, pulmonary embolism, disseminated intravascular coagulation, coronary thrombosis, stroke, and the occlusion of a shunt or stent.

35. A method for providing antithrombotic support in thrombolytic treatment utilizing rt-PA or streptokinase in a patient in need thereof, which comprises administering to the patient a therapeutically effective amount of a compound according one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, wherein E is an R.sub.b NH--C(.dbd.NH)-- group or a physiologically acceptable salt thereof.

36. A method for treating or preventing fibrin-dependent inflammatory processes in a patient in need thereof, which comprises administering to the patient a therapeutically effective amount of a compound according one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, wherein E is an R.sub.b NH--C(.dbd.NH)-- group or a physiologically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc